{
    "data": {
        "studies": [
            {
                "StudyNumber": "ML21768",
                "StudyPhase": "Phase III",
                "StudyIndication": "Colorectal cancer",
                "StudyScientificArea": "Oncology | Gastroenterology",
                "Study_Unq_ID": "00001bd9-da12-4f55-bdb0-a95a392a7640",
                "StudyExecutingParty": "Collaborative Group",
                "Is_Active": 1
            },
            {
                "StudyNumber": "BP15387",
                "StudyPhase": "Phase I",
                "StudyIndication": "Not specified",
                "StudyScientificArea": "",
                "Study_Unq_ID": "00070b13-5b2e-4ed6-8ad2-5325f4496a26",
                "StudyID": "http://clinical.roche.com/study/BP15387",              
                "StudyCITFlag": "N",
                "StudyThemeMolecule": "",
                "StudyScientificTitle": "An ascending dose study of the tolerability, safety, pharmacodynamics, pharmacokinetics of an IV infusion of endothelin antagonist Ro 61-1790 in healthy, male voluteers.", 
                "StudyType": "Interventional1",
                "StudyStatus": "Clinical Closure",
                "StudySource": "AIMS",
                "StudyNonRocheNumber": "",
                "StudySponsorType": "",
                "UpdatedAt": "2024-10-08T17:37:00Z",
                "SourceType": "GIP, RWD",
                "Is_Active": 1
            }
        ]
    }
}